Course content

A list of the course contents is given on the website, link below. It includes a visit to a small-scale biomanufacturing facility. For more in-depth information on course content and structure check

Learning Outcomes 

A. To gain an understanding of the vaccine development process, including GMP manufacture and testing vaccine safety and efficacy in clinical trials.

B.To be able to apply the understanding to vaccines being designed, manufactured and developed by the participant

Course Goals 

  1. To give an overview of vaccine biomanufacturing including considerations for taking pre-clinical vaccine candidates into GMP manufacture, the principles of GMP (good manufacturing practice), and an overview of small to large scale manufacture.

  2. To provide an overview of vaccine clinical development including examples from experimental and licensed vaccines; to impart the importance of clinical trial design, immunomonitoring, statistical considerations and ethical considerations.


Application Deadline:  

15 July 2020

Course Dates:

11-14 May 2021  (4 days)


Wendy Crocker

M1  Clinical vaccine development and biomanufacturing

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 730964.

Be the first to know about the upcoming application calls, follow European Vaccine Initiative on:

  • LinkedIn Social Icon
  • Twitter Social Icon
Subscribe to TRANSVAC´s Mailing list

© 2020 European Vaccine Initiative. Designed by European Vaccine Initiative